BRPI0607574A2 - composição farmacêutica aerossol - Google Patents

composição farmacêutica aerossol

Info

Publication number
BRPI0607574A2
BRPI0607574A2 BRPI0607574-6A BRPI0607574A BRPI0607574A2 BR PI0607574 A2 BRPI0607574 A2 BR PI0607574A2 BR PI0607574 A BRPI0607574 A BR PI0607574A BR PI0607574 A2 BRPI0607574 A2 BR PI0607574A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
administration
poorly soluble
oral
aerosol pharmaceutical
Prior art date
Application number
BRPI0607574-6A
Other languages
English (en)
Inventor
Manfred Keller
Ingo Friedrich
Juergen Jauernig
Frank-Christophe Lintz
Original Assignee
Pari Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pari Pharma Gmbh filed Critical Pari Pharma Gmbh
Publication of BRPI0607574A2 publication Critical patent/BRPI0607574A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçãO FARMACêUTICA AEROSSOL. A presente invenção refere-se composições estéreis para administração como aerossóis. Elas contêm um agente ativo que é pouco solúvel em água, um componente tensoativo não iónico e um componente fosfolipidio. As composições são adequadas para inalação oral ou nasal, mas também para administração tópica ou oromucosa. Elas são particularmente úteis para a administração pulmonar eficiente de corticosteróides pouco solúveis e podem ser aerossolizadas com nebulizadores comuns.
BRPI0607574-6A 2005-04-15 2006-04-06 composição farmacêutica aerossol BRPI0607574A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05008322A EP1712220A1 (en) 2005-04-15 2005-04-15 Pharmaceutical aerosol composition
PCT/EP2006/003147 WO2006108556A2 (en) 2005-04-15 2006-04-06 Pharmaceutical aerosol composition

Publications (1)

Publication Number Publication Date
BRPI0607574A2 true BRPI0607574A2 (pt) 2009-09-15

Family

ID=35456792

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607574-6A BRPI0607574A2 (pt) 2005-04-15 2006-04-06 composição farmacêutica aerossol

Country Status (9)

Country Link
EP (2) EP1712220A1 (pt)
AU (1) AU2006233604B2 (pt)
BR (1) BRPI0607574A2 (pt)
CA (1) CA2604327C (pt)
DK (1) DK1874270T3 (pt)
ES (1) ES2548857T3 (pt)
MX (1) MX2007012802A (pt)
RU (1) RU2007141868A (pt)
WO (1) WO2006108556A2 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2007059515A2 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions of lipoxygenase inhibitors
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
JP5324223B2 (ja) 2005-12-08 2013-10-23 トランセイブ， インク． 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
WO2009040595A1 (en) * 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
AU2008316284A1 (en) * 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
BRPI0918253A2 (pt) 2008-09-12 2015-12-15 Critical Pharmaceuticals Ltd aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele
UA94177C2 (en) * 2010-01-29 2011-04-11 Анатолий Альбертович Кузьмин antimicrobial composition
KR101907411B1 (ko) 2010-03-12 2018-10-12 베르그 엘엘씨 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
TWI602568B (zh) * 2011-04-26 2017-10-21 維克多瑞有限責任公司 以氣膠氣囊之伊洛前列素（ｉｌｏｐｒｏｓｔ）之投藥方法
CN107095863A (zh) 2011-06-17 2017-08-29 博格有限责任公司 可吸入药物组合物
DE102011108948A1 (de) * 2011-07-29 2013-01-31 Achim Göpferich Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
ITRM20120331A1 (it) * 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
KR101313993B1 (ko) * 2012-07-24 2013-10-01 한국화학연구원 약물 흡입 장치
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
KR101586790B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
RU2536425C2 (ru) * 2013-01-17 2014-12-20 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP2886121A1 (de) * 2013-12-23 2015-06-24 Dr. Falk Pharma Gmbh Wässrige Suspension enthaltend Budesonid zur Behandlung von entzündlichen Veränderungen des Ösophagus
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
CA2938994A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Inhalable formulations of sodium cromolyn with improved bioavailability
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
CN105435232A (zh) * 2014-08-08 2016-03-30 深圳君圣泰生物技术有限公司 一种液体制剂组合物及其制备方法、用途和制剂
AU2014403039B2 (en) * 2014-08-08 2020-04-09 Shagnhai Hightide Biopharmaceutical, Ltd. Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
CN105435227A (zh) * 2014-08-08 2016-03-30 深圳君圣泰生物技术有限公司 一种液体制剂组合物及其制备方法、用途和固体制剂
CN105362220A (zh) * 2014-08-08 2016-03-02 深圳君圣泰生物技术有限公司 一种制剂及其制备方法、用途
CN105434346A (zh) * 2014-08-08 2016-03-30 深圳君圣泰生物技术有限公司 一种制剂组合物及其制备方法、用途
US20180169713A1 (en) 2015-01-23 2018-06-21 Pari Pharma Gmbh Method for cleaning a membrane of a membrane aerosol generator, which membrane can vibrate, and combination of a cleaning device and a cleaning liquid for such cleaning
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
MX393629B (es) * 2016-05-31 2025-03-24 Polyphor Ag Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.
PE20190622A1 (es) 2016-06-02 2019-04-26 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
US20170354692A1 (en) * 2016-06-13 2017-12-14 MAM Holdings of West Florida, L.L.C. Amniotic fluid formulation for treatment of lung disorders
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
MA49796A (fr) 2017-12-01 2020-06-03 Abbvie Inc Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019213398A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
CN110876721A (zh) * 2018-09-06 2020-03-13 天津金耀集团有限公司 一种含有表面活性剂的噻托溴铵喷雾剂
CN110876720A (zh) * 2018-09-06 2020-03-13 天津金耀集团有限公司 依地酸盐恰当改变噻托溴铵喷雾剂表面张力的应用
CN110876807A (zh) * 2018-09-06 2020-03-13 天津金耀集团有限公司 一种含有表面活性剂的抗胆碱能药物的喷雾剂
CN110876722A (zh) * 2018-09-06 2020-03-13 天津金耀集团有限公司 一种含有表面活性剂的噻托溴铵奥达特罗喷雾剂
CN110876723A (zh) * 2018-09-06 2020-03-13 天津金耀集团有限公司 一种含有表面活性剂的异丙托溴铵喷雾剂
TWI834808B (zh) * 2019-02-19 2024-03-11 西班牙商薩爾瓦特實驗室有限公司 以單劑包裝的克氯黴唑液體組成物
EP4125805A1 (en) 2020-04-01 2023-02-08 UNION therapeutics A/S Formulation
CA3173163A1 (en) 2020-04-01 2021-10-07 Morten Sommer Treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
CN115484987A (zh) * 2020-04-03 2022-12-16 拜耳公司 液体药物制剂聚乙二醇基肾上腺髓质素前药和用途
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx
CN112274497B (zh) * 2020-11-25 2022-04-15 青岛市中心医院 一种治疗小儿支气管哮喘的药物及其制备方法
CN114681435A (zh) * 2020-12-31 2022-07-01 上海汇伦生物科技有限公司 吸入用药物组合物
CN115404133A (zh) * 2021-05-28 2022-11-29 广州大白生物科技有限公司 一种无刺鼻作用的油污净及其制备方法
WO2023285009A1 (en) * 2021-07-16 2023-01-19 Dripel B.V. Aqueous bumetanide-containing liquid
CN120114390B (zh) * 2025-04-09 2026-03-31 南通香地生物有限公司 一种他克莫司透皮气雾剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU76682A1 (pt) * 1977-02-01 1977-06-27
US4150071A (en) * 1977-08-26 1979-04-17 Respiratory Care, Inc. Nebulizer
DE4203306A1 (de) * 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
DE4322111C2 (de) * 1993-07-02 2001-05-10 Pari Gmbh Inhalationsvernebler
WO1996013254A1 (en) * 1994-10-26 1996-05-09 Glaxo Wellcome House Pharmaceutical composition comprising atovaquone
IT1277832B1 (it) * 1995-03-02 1997-11-12 Giuseppina Magni Confezione per sostanze nebulizzabili
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
WO2000027376A2 (de) 1998-10-26 2000-05-18 Michael Schedler Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus
RU2180217C2 (ru) 2000-03-21 2002-03-10 Закрытое акционерное общество "Пульмомед" Стабильный водный раствор противовоспалительного действия, содержащий будесонид
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0009591D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE10145361A1 (de) 2001-09-14 2003-04-03 Pari Gmbh Verfahren zur Herstellung von flüssigen, sterilen Zubereitungen zur Inhalation
DE10239321B3 (de) 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
RU2327450C2 (ru) * 2002-08-29 2008-06-27 Сипла Лимитед Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung

Also Published As

Publication number Publication date
WO2006108556A3 (en) 2007-05-03
AU2006233604B2 (en) 2012-02-02
EP1874270B1 (en) 2015-08-12
ES2548857T3 (es) 2015-10-21
AU2006233604A1 (en) 2006-10-19
RU2007141868A (ru) 2009-05-20
DK1874270T3 (en) 2015-08-24
EP1712220A1 (en) 2006-10-18
MX2007012802A (es) 2008-02-22
CA2604327A1 (en) 2006-10-19
CA2604327C (en) 2013-10-15
WO2006108556A2 (en) 2006-10-19
EP1874270A2 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
MX2007012802A (es) Composicion farmaceutica en aerosol.
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
WO2008151235A3 (en) Compositions for delivering medicaments into the lungs, uses thereof
ATE311174T1 (de) Wässrige zusammenstellungen die corticosteroide enthalten zur nasalen oder pulmonalen verabreichung
WO2009095681A3 (en) Suspension formulations
PE20091691A1 (es) Formulacion para inhalacion que comprende aclidinio
WO2007091267A3 (en) Pulmonary delivery of alpha-i proteinase inhibitor
NZ600790A (en) Combination therapy for copd
MX2010003935A (es) Suministro de farmaco por inhalacion.
BRPI0609784C1 (pt) compostos éster de n-alquilcarbonil-aminoácido e n-alquilcarbonil-amino lactona, composição, e, uso de um composto
NO20090407L (no) Aerosolformulering for inhalering av beta agonister
WO2009028495A1 (ja) 真菌性皮膚炎用剤
CA2818925A1 (en) Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases
CL2012003450A1 (es) Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
WO2010068754A3 (en) Methods and compositions for delivery of medicaments to the lungs
WO2011141929A3 (en) Aqueous pharmaceutical compositions of fluticasone and olopatadine
BRPI0415470A (pt) preparação em aerossol aquosa
PE20141036A1 (es) Nueva dosificacion y formulacion
WO2007043057A3 (en) Compositions for nasal delivery
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
BRPI0509026A (pt) formulação de aerossol, método para a prevenção e tratamento de infecção causada por bactéria do trato respiratório, e, solução

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06I Technical and formal requirements: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2468 DE 24/04/2018 POR TER SIDO INDEVIDA.

B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal
B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL